InvestorsHub Logo
Followers 105
Posts 4947
Boards Moderated 0
Alias Born 10/20/2015

Re: jakeflies post# 141551

Tuesday, 01/19/2021 8:21:35 PM

Tuesday, January 19, 2021 8:21:35 PM

Post# of 232995
I think HGEN moving endpoint to 28 day survival is smart of HGEN. They are reading the writing on the wall of the impending CYDY approval based on 28 day survival and may have done so in consultation with the FDA so that Lenzilimab will remain relevant after Leronlimab approval and it can be used in this pandemic as well. There is plenty of room for both and both will sell all they can manufacture. I rate both drugs a high probability of approval. Not invested in HGEN but I rate it a strong buy as well as CYDY.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News